A BPC-157 certificate reporting 99% purity is reporting an HPLC area-percent ratio, not a mass fraction. US Patent 8450271 documents one lot at roughly 90% by chromatographic area and 77% peptide content by amino acid analysis on the same material — a 13-point gap that no line item on a purity-only certificate would surface.
A BPC-157 certificate of analysis that reads 99.1% purity is reporting the area of one chromatographic peak divided by the total area of every peak the detector integrated. It is a ratio of signal, not a statement of how much peptide is present in the container by weight. The two numbers are related, and on well-made material they are close, but they are produced by different assays against different references, and the documented distance between them on a single lot of BPC-157 material is large enough to change what a purchase order buys.2,3
This matters now because FDA's 2026 Pharmacy Compounding Advisory Committee briefing document reviewed the certificates already circulating for BPC-157 free base and BPC-157 acetate and found most of them carrying purity results with no impurity limits and no impurity-profile control data at all. A purchasing specification written as "98%+ purity" cannot distinguish those certificates from a fully characterized one.1
What a "Purity" Number on a BPC-157 Certificate Actually Measures
The patent literature indexed against the BPC-157 substance records draws the distinction explicitly. US Patent 12201674 defines chromatographic purity as the main peak area compared with the total area of all detected peaks, and defines peptide content separately as a mass-based concentration calculated against reference standards. These are two rows on a certificate, not two phrasings of one row. A lot can score high on the first while carrying substantial non-peptide mass that the first assay never sees, because the assay only compares peaks to other peaks.3
US Patent 11186608 makes the same split in different vocabulary, describing relative content as a peak area or signal intensity percentage in a chromatogram, as distinct from absolute content expressed as weight percent determined against an external standard. Relative and absolute are the operative words. Area-percent purity answers a question about composition of the detected material; net peptide content answers a question about mass in the vial. A certificate that reports only the first has answered only the first.3
| Certificate line | What it measures | Method basis | What it does not capture |
|---|---|---|---|
| HPLC area-percent purity | Main peak area as a fraction of total integrated peak area | RP-HPLC with UV detection at a stated wavelength and gradient | Any mass that does not absorb at the detection wavelength |
| Net peptide content assay | Peptide mass as a weight fraction of the material supplied | Amino acid analysis or nitrogen determination against a reference standard | Distribution of related peptide impurities within that mass |
| Counterion assay | Identity and quantity of the salt form present | FT-IR, 19F-NMR, or HPLC with evaporative light-scattering detection for TFA | Peptide-related impurities |
| Water content | Residual water as a weight fraction | Karl Fischer titration | Counterion and inorganic salt mass |
A buyer reading only the first row of that table is reading the one row that is insensitive to three of the four non-peptide contributions listed beside it. That is the structural reason two certificates can show the same headline figure and describe materially different lots.3
The Documented Gap: 90% Chromatographic Purity, 77% Peptide Content, Same Lot
The magnitude is not hypothetical, and it is not sourced from a vendor's marketing page. US Patent 8450271, indexed against the BPC-157 acetate substance record, reports a peptide purity of approximately 90% determined by RP-HPLC integrated peak area, and then reports a separate amino acid analysis finding the peptide content of that same material to be 77% by weight. One physical lot, two assays, a thirteen-point spread between the number a certificate would print as "purity" and the number describing peptide mass.2
The RP-HPLC result correctly described the material it detected. The amino acid analysis described the material that was weighed out. Both numbers were accurate reports of different quantities, which is precisely why a certificate carrying one of them cannot be treated as carrying the other.2
Non-peptide mass stacks. Residual counterion, residual water, and inorganic salt carried through from purification each occupy weight in the container, and a certificate that quantifies none of them leaves that entire fraction unbounded. Against a chromatographic figure in the high nineties, an undisclosed non-peptide fraction approaching twenty percent is arithmetically available, and nothing on a purity-only certificate rules it out.2,3
Why Area-Percent and Weight-Percent Diverge: UV Response, Salts, Water, TFA
US Patent 11186608 states the assumption that makes area-percent readable as weight-percent at all: the correlation depends on all peptidic components sharing similar UV response factors. The patent also states where that assumption fails — it does not hold for non-peptide mass such as salts, water, or residual trifluoroacetic acid. Those species either do not absorb at the detection wavelength or do not elute as integrated peaks, so they contribute weight to the container without contributing area to the denominator.3
- UV response factor differences between the main peak and related peptide species, which distort the ratio even when every peak is peptidic.
- Inorganic salts carried through purification and lyophilization, which add mass and are invisible to UV detection at peptide wavelengths.
- Residual water, quantified by Karl Fischer titration and reported as a separate weight fraction, not inferable from a chromatogram.
- Residual trifluoroacetic acid counterion, an artifact of the synthesis route rather than a contaminant introduced by handling.3
The TFA item is the one most often absent from certificates. Solid-phase peptide synthesis relies on trifluoroacetic acid as both a cleavage agent and an ion-pairing reagent, with the consequence that synthetic peptides are routinely isolated as TFA salts. That is a property of the manufacturing route, so it applies by default to synthetic BPC-157 material unless a salt-exchange step is documented and a counterion assay confirms it. Peer-reviewed methodology for quantifying residual TFA counterion includes FT-IR, 19F-NMR, and HPLC with an evaporative light-scattering detector.3
Each of the four contributors above has an established analytical method and a separate certificate row. None of them is measured by the assay that produces the headline purity figure. A specification that names only that figure has therefore specified one of five things a receiving inspection needs.3
The Acetate Counterion Is Part of the Identity, Not a Rounding Error
FDA's 2026 briefing document lists the molecular formula of BPC-157 acetate as C62H98N16O22. The acetate is inside the formula. It is part of the compendial identity of that substance, not a trace residue described in a footnote. The FDA substance registry carries BPC-157 and BPC-157 acetate as separate records with separate identifiers rather than as one entry with a salt annotation.1,2,3
Read against the synthesis facts, this produces a concrete documentation problem. Material isolated as a TFA salt is not, on identity grounds, the acetate substance named in the briefing document. Converting one to the other is a manufacturing step with its own process record and its own analytical confirmation. A certificate headed "BPC-157 acetate" that reports a purity percentage and no counterion assay has asserted the salt form in the product name while providing no data that establishes it.1,3
For a wholesale buyer, that means counterion identity and counterion assay are a distinct line item on an incoming-goods specification, sitting alongside purity rather than inside it. Salt form also determines what the net peptide content figure has to be compared against, since the theoretical peptide fraction of a fully converted acetate salt differs from that of a TFA salt of the same sequence.1,3
What FDA's 2026 PCAC Review Found on the Certificates Already in Circulation
The gap described above is not a theoretical hazard being raised in advance of any evidence. FDA's briefing document for the 2026 Pharmacy Compounding Advisory Committee meeting reviewed certificates of analysis for BPC-157 free base and found that most of them contain only purity testing results, with no impurity limits and no impurity-profile control data. That is a finding about documents suppliers are issuing, described in a federal advisory committee briefing.1
The review also identified a specific BPC-157 acetate certificate of analysis reporting a purity result of 98.34% with no accompanying impurity attribute control data. That certificate is discussed in the public record of a federal advisory committee, without impurity-profile control data of any kind attached to the purity figure.1
BPC-157 free base and BPC-157 acetate were both the subject of a Pharmacy Compounding Advisory Committee vote on inclusion in the 503A bulks list, scheduled for the July 23-24, 2026 meeting. The committee's proceedings, including verbatim transcripts of its earlier peptide-topic sessions, are published as part of the public docket record, which means the analytical deficiencies described in the briefing material are citable by anyone reviewing a supply chain after the fact.4,5
A purchasing specification that accepts any figure above 98% would accept the 98.34% certificate FDA describes without a second question, which is the exact outcome a four-part specification is built to prevent.1
Rewriting the RFQ Line Item: From "98%+ Purity" to a Four-Part Specification
The operational conclusion is narrow: a single purity threshold is not a specification, because it names one assay and silently accepts every result the other assays would have produced. The replacement is four line items plus an impurity requirement, each with a named method and a stated acceptance limit, written into the request for quotation so that a supplier unable to produce the data cannot return a compliant quote.1,2,3
- HPLC area-percent purity, reported with detection wavelength, gradient program, column chemistry, and run time, so the figure can be compared across suppliers rather than taken on trust.
- Net peptide content assay reported as weight percent by amino acid analysis or nitrogen determination against a named reference standard, with its own acceptance limit rather than an inference from the chromatogram.
- Counterion identity and assay, stated as acetate or trifluoroacetate with the quantifying method named — FT-IR, 19F-NMR, or HPLC with evaporative light-scattering detection.
- Water content by Karl Fischer titration, reported as weight percent on the same lot as the purity result.
- Impurity profile with individual and total impurity limits, which FDA's briefing document identifies as the element most often missing from BPC-157 certificates in circulation.1,2,3
| RFQ line item | Rejection trigger at incoming inspection | Failure it catches |
|---|---|---|
| Wavelength and gradient disclosed | Purity figure supplied with no chromatographic conditions | Area-percent figures that cannot be compared lot to lot or supplier to supplier |
| Net peptide content by weight | No mass-based content row on the certificate | The 90%-versus-77% divergence documented on a single lot in US Patent 8450271 |
| Counterion identity and assay | Product named as acetate with no counterion data | TFA-salt material invoiced against an acetate identity |
| Karl Fischer water content | Water content absent or reported as a generic loss-on-drying figure | Undisclosed residual water occupying container fill weight |
| Individual and total impurity limits | Purity result only, as in the 98.34% certificate FDA reviewed | Certificates with no impurity-profile control data of any kind |
Two of those rows — counterion identity and net peptide content — require analytical work that a manufacturer running its own synthesis and quality control already has in place; a reseller sourcing through an intermediary broker typically has no direct line to that data and must go back to the original manufacturer to obtain it. That asymmetry is the point. The specification is not primarily a quality instrument; it is a supplier-qualification instrument that runs before any price discussion.1
Regulatory Status Is Still Moving, Which Is a Reason to Specify Now, Not Wait
A buyer might reasonably ask whether a future compendial monograph will settle all of this and make an internal specification unnecessary. The record points the other way. FDA's May 2021 guidance on abbreviated new drug applications for highly purified synthetic peptide drug products referencing rDNA-origin listed drugs was withdrawn as of a July 2026 notice, on the stated basis that it no longer reflects the agency's current scientific thinking on the subject.1
That withdrawal removes one existing federal reference point on synthetic peptide purity characterization without replacing it, leaving no consolidated guidance in its place. At the same time, BPC-157 free base and BPC-157 acetate remain nominated bulk drug substances scheduled for advisory committee consideration, and nominations for use in compounding are tracked and published as a standing list that changes with each review cycle of the program.5,6
Nothing in that sequence produces a fixed external number a purchasing department can adopt in the interim. What it produces is a window in which the only specification governing incoming BPC-157 research material is the one the buyer writes. Four assays, five certificate rows, named methods, stated limits — issued with the RFQ rather than negotiated after a lot arrives.1,5,6
The cost of skipping it is not abstract. It is a warehouse of vials whose peptide mass is unknown within thirteen points, purchased at a price set as though it were known, documented by certificates that a federal advisory committee has already described in writing as carrying purity results and nothing else.1,2